ArticleCNS neuroscience & therapeutics2022

Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.

Yue-Liang Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.